author-photo

Olga Burenkova

Millennium Pharmaceuticals

28

Papers

735

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

Abstract 1792: Engineered exosome- mediated STAT6 knockdown in tumor associated macrophages (TAMs) results in potent single agent activity in a hepatocellular carcinoma (HCC) model

2021 Immunology
Show All
- Source
- Cite
- Save
Citations (0)
LANGUAGE SITUATION IN EDUCATION: THE EXPERIENCE OF THE FORMER FRENCH COLONIES

2021
Show All
- Source
- Cite
- Save
Citations (0)
842 Exosome mediated reprogramming of tumor associated macrophages by exoASO-STAT6 for the treatment of hepatocellular carcinoma (HCC)

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities.

2021 Journal of the American Chemical Society
Show All
- Source
- Cite
- Save
Citations (2)
Design of BET Inhibitor Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities

2020 ChemRxiv
Show All
- Source
- Cite
- Save
Citations (0)
Abstract A50: Reprogramming of tumor-associated M2 macrophages with antisense oligonucleotide-loaded exosomes results in potent single-agent antitumor activity

2020 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (0)
CD45-Targeted Antibody Drug Conjugate Plus Post Transplant Cytoxan Is Sufficient to Enable Allogeneic Bone Marrow Transplant in a Minor Mismatch Mouse Model

2019 Biology of Blood and Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (1)
The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies

2016 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (39)
Abstract LB-C25: Inhibition of ERBB3 with MM-121, IGF1-R with MM-141 or Met with MM-131 increases the activity of EGFR inhibitor MM-151 in colorectal cancer models expressing multiple resistance ligands

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (1)